Phase 1 Trials of Bayer’s Cell and Gene Therapies Enrolling Patients

Phase 1 Trials of Bayer’s Cell and Gene Therapies Enrolling Patients

296336

Phase 1 Trials of Bayer’s Cell and Gene Therapies Enrolling Patients

A first patient has been dosed in a still-recruiting Phase 1 clinical trial testing DA01, an investigational cell therapy for Parkinson’s disease. A separate Phase 1 trial of a potential gene therapy for Parkinson’s is also recruiting eligible patients in the U.S., according to a press release from Bayer. Parkinson’s is caused by the death of dopamine-producing neurons in the brain. DA01 is made up of dopamine-producing neurons (nerve cells) derived from human embryonic stem…

You must be logged in to read/download the full post.